Cargando…

Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012

OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanni, Emad A., Ferreira, Germano, Guennec, Morgane, El Hahi, Yassine, El Ghachi, Amale, Haguinet, François, Espie, Emmanuelle, Bianco, Veronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009512/
https://www.ncbi.nlm.nih.gov/pubmed/29880565
http://dx.doi.org/10.1136/bmjopen-2017-020528
_version_ 1783333402638811136
author Yanni, Emad A.
Ferreira, Germano
Guennec, Morgane
El Hahi, Yassine
El Ghachi, Amale
Haguinet, François
Espie, Emmanuelle
Bianco, Veronique
author_facet Yanni, Emad A.
Ferreira, Germano
Guennec, Morgane
El Hahi, Yassine
El Ghachi, Amale
Haguinet, François
Espie, Emmanuelle
Bianco, Veronique
author_sort Yanni, Emad A.
collection PubMed
description OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence rate (IR) of HZ in individuals with a wide set of IC conditions and in IC-free individuals. SETTING: A retrospective cohort study was conducted in England using data (January 2000 to March 2012) from the Clinical Practice Research Datalink with linkage to the Hospital Episodes Statistics. PARTICIPANTS: A cohort of 621 588 individuals with 16 selected IC conditions and a gender/age-matched cohort of IC-free individuals were identified. The IC conditions included haematopoietic stem cell transplant (HSCT), solid organ transplant, malignancies, autoimmune diseases and users of immunosuppressive medications. OUTCOMES: IR of HZ per 1000 person-years (PY) was estimated. Proportions of postherpetic neuralgia (PHN) and other HZ complications within 90 days of HZ onset were also estimated among patients with HZ. Risk factors for PHN in IC individuals with HZ were assessed by a multivariate regression model. RESULTS: The overall IR of HZ in the IC cohort was 7.8/1000 PY (95% CI 7.7 to 7.9), increasing with age from 3.5/1000 PY (3.4–3.7) in individuals aged 18–49 years to 12.6/1000 PY (12.2–13.0) in individuals aged ≥80 years. This IR in the IC-free cohort was 6.2/1000 PY (6.1–6.3). The overall IR of HZ varied across IC conditions, ranging from 5.3 (5.1–5.5) in psoriasis to 41.7/1000 PY (35.7–48.4) in HSCT. The proportions of PHN and other HZ complications were 10.7% (10.2–11.1) and 2.9% (2.7–3.2) in the IC cohort, but 9.1% (8.7–9.5) and 2.3% (2.1–2.6) in the IC-free cohort, respectively. CONCLUSION: IC population contributes to the public health burden of HZ in England. Vaccination might be the most preferable HZ preventive measure for the IC population.
format Online
Article
Text
id pubmed-6009512
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60095122018-06-25 Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012 Yanni, Emad A. Ferreira, Germano Guennec, Morgane El Hahi, Yassine El Ghachi, Amale Haguinet, François Espie, Emmanuelle Bianco, Veronique BMJ Open Public Health OBJECTIVES: Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus which remains latent in individuals after a varicella infection. It is expected that HZ will be more frequent in immunocompromised (IC) individuals than in immunocompetent (IC-free). This study assessed the incidence rate (IR) of HZ in individuals with a wide set of IC conditions and in IC-free individuals. SETTING: A retrospective cohort study was conducted in England using data (January 2000 to March 2012) from the Clinical Practice Research Datalink with linkage to the Hospital Episodes Statistics. PARTICIPANTS: A cohort of 621 588 individuals with 16 selected IC conditions and a gender/age-matched cohort of IC-free individuals were identified. The IC conditions included haematopoietic stem cell transplant (HSCT), solid organ transplant, malignancies, autoimmune diseases and users of immunosuppressive medications. OUTCOMES: IR of HZ per 1000 person-years (PY) was estimated. Proportions of postherpetic neuralgia (PHN) and other HZ complications within 90 days of HZ onset were also estimated among patients with HZ. Risk factors for PHN in IC individuals with HZ were assessed by a multivariate regression model. RESULTS: The overall IR of HZ in the IC cohort was 7.8/1000 PY (95% CI 7.7 to 7.9), increasing with age from 3.5/1000 PY (3.4–3.7) in individuals aged 18–49 years to 12.6/1000 PY (12.2–13.0) in individuals aged ≥80 years. This IR in the IC-free cohort was 6.2/1000 PY (6.1–6.3). The overall IR of HZ varied across IC conditions, ranging from 5.3 (5.1–5.5) in psoriasis to 41.7/1000 PY (35.7–48.4) in HSCT. The proportions of PHN and other HZ complications were 10.7% (10.2–11.1) and 2.9% (2.7–3.2) in the IC cohort, but 9.1% (8.7–9.5) and 2.3% (2.1–2.6) in the IC-free cohort, respectively. CONCLUSION: IC population contributes to the public health burden of HZ in England. Vaccination might be the most preferable HZ preventive measure for the IC population. BMJ Publishing Group 2018-06-07 /pmc/articles/PMC6009512/ /pubmed/29880565 http://dx.doi.org/10.1136/bmjopen-2017-020528 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Public Health
Yanni, Emad A.
Ferreira, Germano
Guennec, Morgane
El Hahi, Yassine
El Ghachi, Amale
Haguinet, François
Espie, Emmanuelle
Bianco, Veronique
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title_full Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title_fullStr Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title_full_unstemmed Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title_short Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
title_sort burden of herpes zoster in 16 selected immunocompromised populations in england: a cohort study in the clinical practice research datalink 2000–2012
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009512/
https://www.ncbi.nlm.nih.gov/pubmed/29880565
http://dx.doi.org/10.1136/bmjopen-2017-020528
work_keys_str_mv AT yanniemada burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT ferreiragermano burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT guennecmorgane burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT elhahiyassine burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT elghachiamale burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT haguinetfrancois burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT espieemmanuelle burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012
AT biancoveronique burdenofherpeszosterin16selectedimmunocompromisedpopulationsinenglandacohortstudyintheclinicalpracticeresearchdatalink20002012